No Data
No Data
Piper Sandler Keeps Their Buy Rating on Ocular Therapeutix (OCUL)
Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Why We're Not Concerned About Ocular Therapeutix, Inc.'s (NASDAQ:OCUL) Share Price
William Blair Initiates Ocular Therapeutix(OCUL.US) With Buy Rating, Announces Target Price $18
Needham Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $15
Express News | William Blair Initiates Coverage On Ocular Therapeutix With Outperform Rating
70581059 : a great buying opportunity in general. if the tariff stays, it has already been priced in. in case not, it will surge back.